MASTER DAPT AMI
![MASTER DAPT](/sites/g/files/qlpvch321/files/2022-09/clinical_evidence_master_dapt_logo.png)
Overview
![Icon of magnigying glass (image)](/sites/g/files/qlpvch321/files/styles/large/public/2022-09/clinical_evidence_master_dapt_icon_magnifying_glass_200x200_0.png?itok=HTHomZVv)
Investigator-initiated
global randomized study
global randomized study
![Icon of globe (image)](/sites/g/files/qlpvch321/files/styles/large/public/2022-09/clinical_evidence_master_dapt_icon_globe_200x200_0.png?itok=Hlrq13LZ)
4,579 patients,
140 hospital worldwide, 30 countries
140 hospital worldwide, 30 countries
![Icon of stethoscope (image)](/sites/g/files/qlpvch321/files/styles/large/public/2022-09/clinical_evidence_master_dapt_icon_stethoscope_200x200_0.png?itok=2I1QfBYt)
All-comers trial in
HBR patients after PCI
HBR patients after PCI
![Icon of microscope (image)](/sites/g/files/qlpvch321/files/styles/large/public/2022-09/clinical_evidence_master_dapt_icon_microscope_200x200_0.png?itok=_yzFGiak)
Abbreviated vs prolonged
DAPT in patients treated with
the Ultimaster™and Ultimaster™ Tansei™ DES
DAPT in patients
treated with the
Ultimaster™ and
Ultimaster™Tansei™
DES
treated with the
Ultimaster™ and
Ultimaster™Tansei™
DES
Primary Endpoint
- Net adverse clinical events (NACE) defined as a composite of death from any cause, myocardial infarction, stroke or major bleeding.
- Major adverse cardiac and cerebrovascular events (MACCE), defined as a composite of death from any cause, myocardial infarction, stroke or major bleeding.
- Major or clinically relevant non-major bleeding (MCB), defined as BARC 2, 3 or 5 bleeding.
Result
NACE
All cause death, Myocardial infection, Stroke and BARC 3 or 5 Bleeding
Prior MI HR 0.83, 95% CI 0.61-1.12; p=0.22
No prior MI HR HR 1.03, 95% CI 0.77-1.38; p=0.85
Pinteraction=0.30
MACCE
All cause death, Myocardial infection, Stroke
Prior MI HR 0.86, 95% CI 0.62-1.19; p=0.236
No prior MI HR 1.13, 95% CI 0.80-1.59; p=0.48
Pinteraction=0.25
MASTER DAPT study is sponsored by the European Cardiovascular Research Institute (ECRI, Rotterdam, The Netherlands) and supported with a restricted research grant by Terumo Europe.